Christina Baik, MD, MPH

Christina Baik, MD, MPH

Associate Professor
Seattle Cancer Care Alliance
Thoracic/Head and Neck
Department of Medicine , Division of Medical Oncology

Mailing Address

Seattle Cancer Care Alliance
825 Eastlake Ave E, G4-940
Seattle, WA 98109-1023

Admin Contact

Melissa Roa

Specialty / Expertise

  • Head, Neck, and Lung

Research Interests

  • Head and neck and lung cancer.

Current Research Projects



Dr. Baik received her MD from the University of Rochester School of Medicine In Rochester, New York and her Masters in Public health from Harvard School of Public Health, Boston, Massachusetts. She completed her Internal Medicine Residency at Brown Medical School, Providence, Rhode Island in 2005. She completed Hematology-Oncology clinical fellowship at Tufts Medical Center, Boston, MA and completed her post-doctorate fellowship here at the Fred Hutchinson Cancer Research Center, Seattle, WA.

Selected Publications

Baik CS, Myall NJ, Wakelee H. Targeting BRAF-mutant non-small cell lung cancer: From molecular profiling to rationally designed therapy. Oncologist. 2017 May 9. pii: theoncologist.2016-0458. doi: 10.1634/theoncologist.2016-0458.

Jacky J, Baik CS. Symptom management strategies for patients receiving anaplastic lymphoma kinase (ALK) inhibitors for non-small cell lung cancer. The Journal of Advanced Practitioner. J Adv Pract Oncol. 2017 Nov-Dec; 8(7):729-735.

Baik CS, Rubin EH, Forde PM, Mehnert JM, Collyar D, Bulter MO, Dixon E, Chow LQM. Immuno-Oncology Clinical Trial Design: Limitations, Challenges and Opportunities. 2017 Sept 23(17): 4992-5002

Rodriguez C, Eaton K, Goulart B, Martins RG, Baik C, Chow L, Santana-Davila R, Lee S. A Phase II trial of eribulin mesylate in recurrent or metastatic salivary gland malignancies. Head Neck. 2018 Mar; 40(3):584-589.

Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deekan J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DP, Ma PC, Raez LE, HEchtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM. Efficacy of Larotrectenib in TRK fusion-positive cancers in Adults and Children. NEJM 2018 Feb 22;378(8): 731-739.

Last updated: October 2018